What you should know:
1. The ophthalmology pharmaceutical company created the role for Dr. Duker.
2. Dr. Duker will lead the strategic advancement of research and development efforts, while continuing his practice at Boston-based Tufts Medical Center.
3. He’ll initially focus on EYP-1901, a wet age-related macular degeneration treatment candidate.
EyePoint President and CEO Nancy Lurker said, “We are delighted to have Jay join our executive team as our Chief Strategic Scientific Officer bringing his world class experience as a retinal specialist to EYP-1901.”
More articles on surgery centers:
Top-paying jobs in 2020 — Surgeons are No. 1
The state of ASCs in June 2020: 10 observations on supply chain, payers, staffing & future growth
Optum leads $26M funding round for digital therapeutics startup
